MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients

Conference Reports for NATAP

17th International Workshop
on Clinical Pharmacology of
HIV and Hepatitis Therapy
June 8-10, 2016, Washington DC


MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients

	Reported by Jules Levin 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 10, 2016 Washington, DC Nancy Kim1*, Wei Gao1, Xiaoli Shirley Glasgow1, Leticia Arrington1, Tami Crumley1, Marie- Francoise Temam1, Edward Gane2, Wouter Haazen3, Serghei Popa4, Eric Sicard5, Catherine Stedman6, William L. Marshall1, John Sullivan-Bolyai1, and Eugene E. Marcantonio1 1Merck & Co., Kenilworth, NJ, USA 2Auckland City Hospital, Auckland, NZ 3SGS Life Sciences Services, Antwerp, Belgium 4Republican Clinical Hospital, Chisinau, Moldova 5Algorithme Pharma, Montreal, Canada 6Christchurch Clinical Studies Trust, Christchurch, NZ EASL:High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16) EASL:In a 5-day Monotherapy Trial, MK-8408 Demonstrated Potent Antiviral Activity and Improved Resistance Profile in HCV Patients With Genotypes 1, 2, and 3 Infections - (04/18/16)